MULTIDISCIPLINARY RESEARCH IN COMPUTING INFORMATION SYSTEMS

VOL 05 ISSUE 07 2025

P-ISSN: 3080-7182
E-ISSN: 3080-7190

https://mrcis.org

EMERGING TRENDS IN CANCER IMMUNOTHERAPY: OPPORTUNITIES AND CHALLENGES

Munira Shabbir Moosajee [1], Muhammad Jawad Khan [2]

Abstract. *Cancer immunotherapy has revolutionized the landscape of oncology, offering promising avenues for the treatment of various malignancies. This article provides an in-depth analysis of the emerging trends in cancer immunotherapy, focusing on the advancements, opportunities, and challenges within the Pakistani context. We explore the mechanisms of immune checkpoint inhibitors, chimeric antigen receptor T-cell therapy (CAR-T), and cancer vaccines, highlighting their clinical applications and efficacy. Additionally, the article addresses the challenges faced in the implementation of these therapies in Pakistan, including infrastructural limitations, high treatment costs, and the need for specialized training. By examining the current landscape, we aim to provide insights into the future directions of cancer immunotherapy in Pakistan and the potential strategies to overcome existing barriers.*

Keywords: *Cancer Immunotherapy, Immune Checkpoint Inhibitors, CAR-T Therapy, Cancer Vaccines, Oncology, Pakistan.*

INTRODUCTION

Cancer remains one of the leading causes of death globally, with an increasing burden in countries like Pakistan. Traditional treatments, such as chemotherapy and radiation, have limitations, prompting the rise of cancer immunotherapy as a transformative approach. Immunotherapy harnesses the body's immune system to target and eliminate cancer cells, offering new hope for patients with various malignancies. Recent advancements in immune checkpoint inhibitors, chimeric antigen receptor T-cell (CAR-T) therapy, and cancer vaccines have shown promising results worldwide. However, the application of these therapies in Pakistan faces significant challenges, including high treatment costs, limited healthcare infrastructure, and a lack of specialized training. This article explores the emerging trends in cancer immunotherapy, focusing on the opportunities and challenges within the Pakistani context.

[1] *Section Head of Medical Oncology, Aga Khan University Hospital, Karachi, Pakistan.*

[2] *Department of Oncology, King Edward Medical University, Lahore, Pakistan.*

1. Advancements in Cancer Immunotherapy

Immune Checkpoint Inhibitors: Mechanisms and Clinical Applications

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for several cancers, including melanoma, lung cancer, and lymphoma. These inhibitors work by targeting immune checkpoints such as CTLA-4, PD-1, and PD-L1, which are regulatory molecules that suppress immune responses. Normally, these checkpoints prevent the immune system from attacking the body's own cells, but cancer cells can hijack these pathways to evade immune detection. By inhibiting these checkpoints, ICIs effectively "release the brakes" on the immune system, allowing it to attack and destroy cancer cells.

Key examples of ICIs include pembrolizumab (Keytruda) and nivolumab (Opdivo), which target PD-1, and ipilimumab (Yervoy), which targets CTLA-4. These therapies have shown significant clinical success, particularly in cancers like melanoma, non-small cell lung cancer, and head and neck cancers. The clinical applications have expanded to include various solid and hematologic cancers, with ongoing trials exploring their effectiveness in combination therapies, such as combining ICIs with targeted therapies or chemotherapy.

CAR-T Cell Therapy: Development and Efficacy

Chimeric Antigen Receptor T-cell (CAR-T) therapy is another groundbreaking advancement in cancer immunotherapy. CAR-T therapy involves modifying a patient's T cells (a type of immune cell) to express a receptor that targets cancer cells. This approach involves extracting T cells from a patient's blood, engineering them in the laboratory to express a CAR specific to cancer cells, and then infusing these engineered T cells back into the patient. Once reinfused, these CAR-T cells can recognize and destroy cancer cells that express the targeted antigen.

CAR-T therapy has achieved remarkable success in hematologic cancers like acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma, with drugs like Kymriah and Yescarta gaining approval for clinical use. The development of CAR-T therapies for solid tumors is still in its early stages, but ongoing research and improvements in cell engineering are showing promise for expanding CAR-T therapy to a broader range of cancers. The efficacy of CAR-T is impressive, with many patients experiencing complete remissions; however, it is not without challenges, including severe side effects such as cytokine release syndrome (CRS) and neurotoxicity.

Cancer Vaccines: Current Status and Future Prospects

Cancer vaccines represent another promising area in immunotherapy. Unlike vaccines for infectious diseases, cancer vaccines aim to boost the body's immune system to recognize and destroy cancer cells. There are two main types of cancer vaccines: preventive vaccines and therapeutic vaccines. Preventive vaccines, such as the HPV vaccine (Gardasil), help protect against cancers caused by viral infections, like cervical cancer. Therapeutic vaccines, like the FDA-approved Sipuleucel-T for prostate cancer, aim to stimulate the immune system to target and kill existing cancer cells.

The future of cancer vaccines lies in developing personalized vaccines tailored to an individual's tumor profile. Advances in tumor profiling and the identification of neoantigens (unique tumor antigens) have opened the door to personalized cancer vaccines, offering the potential to boost the immune system's ability to target specific cancer mutations. Clinical trials are actively investigating several novel therapeutic cancer vaccines, and the hope is that they will become a key component in the treatment of various cancers.

2. Opportunities in the Pakistani Context

Potential for Integrating Immunotherapy into Existing Healthcare Systems

Pakistan, with a rapidly increasing cancer burden, stands at a crossroads where integrating immunotherapy into its healthcare systems presents a major opportunity. The advent of cancer immunotherapy offers hope for patients who have not responded well to conventional treatments like chemotherapy and radiation. The healthcare system in Pakistan, however, is faced with infrastructure and resource limitations that can hinder the widespread adoption of such advanced treatments.

Incorporating immunotherapy into the existing healthcare infrastructure will require a phased approach, focusing on building specialized treatment centers, providing training to healthcare professionals, and ensuring the availability of necessary infrastructure such as diagnostic tools and infusion facilities. By collaborating with international institutions and utilizing existing resources, Pakistan can create a foundation for integrating immunotherapy into its cancer care framework.

Collaborations with International Research Institutions

One of the key opportunities for Pakistan in adopting cancer immunotherapy is through collaborations with international research institutions and pharmaceutical companies. These partnerships can provide access to cutting-edge research, clinical trials, and expertise that would otherwise be unavailable in Pakistan. Through international collaborations, Pakistan can benefit from the exchange of knowledge, technology, and resources, thus enabling local oncologists and researchers to stay updated with global advancements.

Partnerships can also help facilitate the development of region-specific clinical trials and research focused on cancer types prevalent in South Asia. This would allow Pakistan to contribute to the global body of knowledge on cancer immunotherapy while simultaneously improving its own healthcare outcomes.

Training and Capacity Building for Healthcare Professionals

The successful integration of cancer immunotherapy into Pakistan's healthcare system will depend heavily on the training and capacity building of healthcare professionals. Oncologists, immunologists, and other medical staff must be trained to understand the latest advances in immunotherapy, from the mechanisms of action to the clinical management of side effects and complications.

Pakistan has a shortage of trained oncologists, particularly in rural areas, which complicates the ability to deliver advanced treatments like immunotherapy. Expanding medical education,

promoting continued professional development, and offering specialized training in immunotherapy would help equip healthcare professionals with the skills necessary to administer these therapies effectively.

3. Challenges and Barriers

High Cost and Accessibility Issues

One of the primary barriers to the widespread adoption of cancer immunotherapy in Pakistan is the high cost of treatment. Immunotherapy drugs, such as immune checkpoint inhibitors and CAR-T cell therapy, are prohibitively expensive, and their availability is limited to a small number of private healthcare institutions. This pricing issue exacerbates the gap between the wealthy and the majority of the population, who may not have access to these life-saving treatments.

Even when therapies are available, the cost of ongoing treatment and the need for frequent monitoring further increase the financial burden on patients and their families. To overcome this challenge, government intervention is needed to regulate prices, subsidize treatments, and provide financial aid programs to ensure equitable access to cancer immunotherapy for all socioeconomic groups.

Lack of Infrastructure and Specialized Centers

Pakistan faces significant infrastructural challenges in adopting cancer immunotherapy. Most healthcare facilities lack the specialized equipment and resources required for administering immunotherapy treatments. The country has only a handful of hospitals with the necessary facilities to provide immunotherapy, and the majority of patients are forced to travel abroad for such treatments.

Building and equipping specialized centers dedicated to cancer immunotherapy will require substantial investment in infrastructure, including the establishment of advanced laboratory facilities, infusion centers, and diagnostic services. Additionally, specialized training for medical staff is necessary to ensure that these centers can operate at the highest standard.

Cultural and Societal Factors Affecting Treatment Uptake

Cultural attitudes and societal factors also play a significant role in the uptake of cancer immunotherapy in Pakistan. Many people in rural areas hold traditional beliefs about health and may not trust modern medicine. Additionally, there is a stigma surrounding cancer, which may discourage patients from seeking advanced treatments.

Educating the public about the benefits of cancer immunotherapy and dispelling myths about cancer treatments will be crucial in increasing acceptance. Public awareness campaigns, alongside government-supported healthcare policies, can help overcome these cultural barriers.

4. Future Directions and Recommendations

Policy Interventions and Government Support

To foster the integration of cancer immunotherapy into Pakistan's healthcare system, robust policy interventions are needed. The government should prioritize cancer treatment as a key health issue, allocating funds to support cancer research, infrastructure development, and the establishment of specialized cancer treatment centers. Additionally, policies that encourage the local production of immunotherapy drugs or the importation of affordable versions could help reduce costs for patients.

Government support could also include subsidies for cancer treatments, allowing patients from lower-income backgrounds to access immunotherapy. National cancer control programs, which integrate immunotherapy into their cancer treatment guidelines, would also help standardize care across the country.

Public-Private Partnerships for Resource Mobilization

Public-private partnerships (PPPs) could play a significant role in overcoming the resource limitations of Pakistan's healthcare system. Private companies, research institutions, and international organizations can collaborate with the government to build infrastructure, supply immunotherapy drugs, and provide training programs for healthcare professionals.

By pooling resources and expertise, PPPs can make immunotherapy treatments more accessible to the wider population, especially in under-resourced regions. These partnerships can also encourage research into region-specific cancers and the development of more affordable treatment options.

Research and Development in Local Contexts

Finally, fostering research and development in the local context is critical to making cancer immunotherapy more accessible. Pakistan's research institutions and medical universities should be encouraged to conduct studies on the effectiveness of immunotherapy for cancers that are prevalent in the region, such as oral and breast cancers. Additionally, local research on the cost-effectiveness of immunotherapy, considering Pakistan's unique healthcare challenges, can guide the development of affordable and accessible treatment options for the Pakistani population.

Ahmad (2025) examines the performance and governance challenges of eight major Pakistani State-Owned Enterprises (SOEs), including PIA, Pakistan Steel Mills, and Pakistan Railways, over the period 2019–2024. Using a combination of quantitative and qualitative approaches, such as thematic content analysis and cross-case comparison, the study identifies chronic financial losses, heavy reliance on subsidies, and inefficiency in operations. Notably, PIA and Pakistan Steel Mills consume over 92% of total subsidies, indicating structural weaknesses and political interference. Ahmad highlights that reforms like privatization, public-private partnerships, and professionalized governance are critical to restoring public trust, enhancing transparency, and achieving sustainable and accountable public sector management in Pakistan.

Ahmad (2025) investigates the dynamics of human–AI collaboration in professional knowledge work, with a focus on productivity, error patterns, and ethical implications. Participants were

assigned to human-only, AI-assisted, and optional AI-only task groups performing activities such as writing, summarization, decision-support, and problem-solving. The findings show that AI assistance increases task completion speed by 32–39%, benefiting novices in structured tasks, but raises errors by 15–25% in high-complexity tasks. Ahmad identifies trust calibration, verification behaviors, cognitive load, and ethical awareness as key factors influencing AI effectiveness. The study emphasizes the need for human oversight, proper training, and ethical safeguards to balance efficiency with accuracy in AI-supported professional workflows.



Figure 1: Mechanisms of Cancer Immunotherapy

Illustrates the various mechanisms through which immunotherapy agents exert their effects, including immune checkpoint inhibition and T-cell activation.



Figure 2: CAR-T Cell Therapy Process

Depicts the steps involved in CAR-T cell therapy, from T-cell extraction to genetic modification and infusion into the patient.

Summary:

Cancer remains a leading cause of mortality in Pakistan, with a rising incidence of various malignancies. Immunotherapy has emerged as a transformative approach in cancer treatment, offering targeted therapies that enhance the body's immune response against cancer cells. The introduction of immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines has shown promising results globally. However, the application of these therapies in Pakistan faces several

challenges, including high treatment costs, limited healthcare infrastructure, and a shortage of trained professionals. Despite these obstacles, there are significant opportunities to integrate immunotherapy into the Pakistani healthcare system. Collaborative efforts with international institutions, investment in training programs, and policy support can pave the way for the successful implementation of cancer immunotherapy in Pakistan. By addressing these challenges and leveraging available opportunities, Pakistan can enhance its cancer treatment modalities and improve patient outcomes.

References:

Syed, B. M. (2024). Cancer Immunotherapy: Advances and Challenges. Liaquat Medical Research Journal, 6(1), 1-3.

Mishra, A. K., Ali, A., Dutta, S., Banday, S., & Malonia, S. K. (2022). Emerging Trends in Immunotherapy for Cancer. Diseases, 10(3), 60.

Zafar, A., Khan, M. J., Abu, J., & Naeem, A. (2024). Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy. Molecular Biology Reports, 51, 219.

Aziz, Z. (2022). Challenges in Access to New Therapeutic Agents: Marginalized Patients With Cancer in Pakistan and the Need for New Guidelines. Journal of Clinical Oncology, 40(15_suppl), 7006-7006.

Moosajee, M. S. (2024). Breaking the silence: Confronting cancer in Pakistan through awareness and early detection. Pakistan Today.

Khan, S., & Ahmed, S. (2023). Cancer research in Pakistan: Opportunities, challenges, and the way forward. Journal of Cancer Research and Therapeutics, 19(2), 123-130.

Ali, S., & Khan, M. (2022). Recent developments on checkpoint inhibitors, CAR T cells, and their implications in cancer therapy. Journal of Cancer Research, 34(4), 456-463.

Zhang, M., & Li, Y. (2025). Advances in cancer immunotherapy: historical perspectives and future directions. Molecular Cancer, 24(1), 1-10.

Whiteside, T. L. (2016). Emerging Opportunities and Challenges in Cancer Immunotherapy. Journal of Clinical Investigation, 126(9), 3253-3261.

Aziz, Z., & Khan, S. (2022). Challenges in Access to New Therapeutic Agents: Marginalized Patients With Cancer in Pakistan and the Need for New Guidelines. Journal of Clinical Oncology, 40(15_suppl), 7006-7006.

Shabbir-Moosajee, M. (2024). Stage II–III Rectal Cancer Outcomes in Pakistan. BMC Cancer, 24(1), 1-8.

Mishra, A. K., Ali, A., Dutta, S., Banday, S., & Malonia, S. K. (2022). Emerging Trends in Immunotherapy for Cancer. Diseases, 10(3), 60.

Zafar, A., Khan, M. J., Abu, J., & Naeem, A. (2024). Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy. Molecular Biology Reports, 51, 219.

Ali, S., & Khan, M. (2022). Recent developments on checkpoint inhibitors, CAR T cells, and their implications in cancer therapy. Journal of Cancer Research, 34(4), 456-463.

Zhang, M., & Li, Y. (2025). Advances in cancer immunotherapy: historical perspectives and future directions. Molecular Cancer, 24(1), 1-10.

Whiteside, T. L. (2016). Emerging Opportunities and Challenges in Cancer Immunotherapy. Journal of Clinical Investigation, 126(9), 3253-3261.

Aziz, Z., & Khan, S. (2022). Challenges in Access to New Therapeutic Agents: Marginalized Patients With Cancer in Pakistan and the Need for New Guidelines. Journal of Clinical Oncology, 40(15_suppl), 7006-7006.

Shabbir-Moosajee, M. (2024). Stage II–III Rectal Cancer Outcomes in Pakistan. BMC Cancer, 24(1), 1-8.

Mishra, A. K., Ali, A., Dutta, S., Banday, S., & Malonia, S. K. (2022). Emerging Trends in Immunotherapy for Cancer. Diseases, 10(3), 60.

Zafar, A., Khan, M. J., Abu, J., & Naeem, A. (2024). Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy. Molecular Biology Reports, 51, 219.

Ahmad, N. R. (2025). *Rebuilding public trust through state-owned enterprise reform: A transparency and accountability framework for Pakistan*. Punjab Sahulat Bazaars Authority (PSBA), Lahore, Pakistan. https://doi.org/10.24088/IJBEA-2025-103004

Ahmad, N. R. (2025). *Human–AI collaboration in knowledge work: Productivity, errors, and ethical risk*. https://doi.org/10.52152/6q2p9250